Details for New Drug Application (NDA): 215151
✉ Email this page to a colleague
The generic ingredient in VOQUEZNA is amoxicillin; clarithromycin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; vonoprazan fumarate profile page.
Summary for 215151
| Tradename: | VOQUEZNA |
| Applicant: | Phathom |
| Ingredient: | vonoprazan fumarate |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 215151
Generic Entry Date for 215151*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 215151
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VOQUEZNA | vonoprazan fumarate | TABLET;ORAL | 215151 | NDA | Phathom Pharmaceuticals Inc. | 81520-100 | 81520-100-30 | 30 TABLET in 1 BOTTLE, PLASTIC (81520-100-30) |
| VOQUEZNA | vonoprazan fumarate | TABLET;ORAL | 215151 | NDA | Phathom Pharmaceuticals Inc. | 81520-200 | 81520-200-30 | 30 TABLET in 1 BOTTLE, PLASTIC (81520-200-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Nov 1, 2023 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | May 3, 2032 | ||||||||
| Regulatory Exclusivity Use: | GENERATING ANTIBIOTIC INCENTIVES NOW | ||||||||
| Regulatory Exclusivity Expiration: | May 3, 2027 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Regulatory Exclusivity Expiration: | Nov 1, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Complete Access Available with Subscription
